给编辑的信:外用0.5%溴胺凝胶来掩盖未成熟疤痕的红肿。

Markus Reinholz, Markus Heppt, Julia K Tietze, Thomas Ruzicka, Gerd G Gauglitz, Jürgen Schauber
{"title":"给编辑的信:外用0.5%溴胺凝胶来掩盖未成熟疤痕的红肿。","authors":"Markus Reinholz,&nbsp;Markus Heppt,&nbsp;Julia K Tietze,&nbsp;Thomas Ruzicka,&nbsp;Gerd G Gauglitz,&nbsp;Jürgen Schauber","doi":"10.3315/jdcr.2015.1210","DOIUrl":null,"url":null,"abstract":"<p><p>Cutaneous scars develop as a result of a defective wound healing process. Scars are commonly visible as erythematous, sometimes disfiguring lesions which might be stigmatizing for the affected patient. Only a few therapies to improve the appearance of scars are available. Recently, brimonidine - a selective α2-receptor-agonist which causes vasoconstriction of small cutaneous vessels - was approved for the treatment of erythemato-telangiectatic rosacea. Topical brimonidine might also be helpful to improve redness of immature scars. Here we report on the effect of brimonidine 0.5% gel on a flat, erythematous scar in a 25-year-old female patient. Whitening of the scar could be observed immediately after application of brimonidine 0.5% gel and a good clinical result was observed within one hour. This effect lasted for up to three hours. We conclude that brimonidine 0.5% gel is a suitable topical therapy to reduce erythema in visible cutaneous scars. </p>","PeriodicalId":15601,"journal":{"name":"Journal of dermatological case reports","volume":"9 3","pages":"87-8"},"PeriodicalIF":0.0000,"publicationDate":"2015-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619167/pdf/jdcr-09-087.pdf","citationCount":"3","resultStr":"{\"title\":\"Photoletter to the editor: Topical 0.5% brimonidine gel to camouflage redness of immature scars.\",\"authors\":\"Markus Reinholz,&nbsp;Markus Heppt,&nbsp;Julia K Tietze,&nbsp;Thomas Ruzicka,&nbsp;Gerd G Gauglitz,&nbsp;Jürgen Schauber\",\"doi\":\"10.3315/jdcr.2015.1210\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cutaneous scars develop as a result of a defective wound healing process. Scars are commonly visible as erythematous, sometimes disfiguring lesions which might be stigmatizing for the affected patient. Only a few therapies to improve the appearance of scars are available. Recently, brimonidine - a selective α2-receptor-agonist which causes vasoconstriction of small cutaneous vessels - was approved for the treatment of erythemato-telangiectatic rosacea. Topical brimonidine might also be helpful to improve redness of immature scars. Here we report on the effect of brimonidine 0.5% gel on a flat, erythematous scar in a 25-year-old female patient. Whitening of the scar could be observed immediately after application of brimonidine 0.5% gel and a good clinical result was observed within one hour. This effect lasted for up to three hours. We conclude that brimonidine 0.5% gel is a suitable topical therapy to reduce erythema in visible cutaneous scars. </p>\",\"PeriodicalId\":15601,\"journal\":{\"name\":\"Journal of dermatological case reports\",\"volume\":\"9 3\",\"pages\":\"87-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619167/pdf/jdcr-09-087.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of dermatological case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3315/jdcr.2015.1210\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of dermatological case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3315/jdcr.2015.1210","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

摘要

皮肤疤痕是由于伤口愈合过程的缺陷而产生的。疤痕通常是可见的红斑,有时毁容的病变,这可能是受影响的病人的耻辱。只有几种治疗方法可以改善疤痕的外观。最近,溴莫尼定-一种选择性α2受体激动剂,可引起小皮肤血管收缩-被批准用于治疗红斑毛细血管扩张型酒痤疮。局部使用溴硝定也可能有助于改善未成熟疤痕的发红。在这里,我们报告0.5%溴莫尼定凝胶对25岁女性患者扁平红斑疤痕的影响。0.5%溴莫尼定凝胶敷后即刻可观察到瘢痕的增白,1小时内临床效果良好。这种效果持续了三个小时。我们认为0.5%溴莫尼定凝胶是一种合适的局部治疗方法,可以减少可见皮肤疤痕的红斑。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Photoletter to the editor: Topical 0.5% brimonidine gel to camouflage redness of immature scars.

Cutaneous scars develop as a result of a defective wound healing process. Scars are commonly visible as erythematous, sometimes disfiguring lesions which might be stigmatizing for the affected patient. Only a few therapies to improve the appearance of scars are available. Recently, brimonidine - a selective α2-receptor-agonist which causes vasoconstriction of small cutaneous vessels - was approved for the treatment of erythemato-telangiectatic rosacea. Topical brimonidine might also be helpful to improve redness of immature scars. Here we report on the effect of brimonidine 0.5% gel on a flat, erythematous scar in a 25-year-old female patient. Whitening of the scar could be observed immediately after application of brimonidine 0.5% gel and a good clinical result was observed within one hour. This effect lasted for up to three hours. We conclude that brimonidine 0.5% gel is a suitable topical therapy to reduce erythema in visible cutaneous scars.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信